VIVUS Inc

VIVUS — Technical Presentation (July 2010)

17 slides from VIVUS's technical presentation, Jul 12, 2010

  1. Slide 1: Low-Dose, Controlled-Release Phentermine/Topiramate for Weight Reduction in Overweight/Obese Adults

    Kishore M. Gadde, MD Duke University Medical Center Wesley W. Day, PhD VIVUS Low-Dose, Controlled-Release Phentermine/Topiramate for Reduction of Weight, Related Risks in Overweight/Obese Adults With >2 Comorbidities

  2. Slide 2: Author Disclosure

    Author Disclosure Past 2 years Kishore M. Gadde Research support: BMS; Forest Labs; NIDDK; Pfizer; Vivus, Inc. Stock/shareholder: Orexigen Wesley W. Day Employee: Vivus, Inc.

  3. Slide 3: Background

    Background Phentermine (PHEN) is a sympathomimetic drug approved in the United States for short-term treatment of obesity1 Topiramate (TPM), indicated for treatment of epilepsy and prevention of migraine headache; has demonstrated weight loss, cardiometabolic benefits in clinical trials2-8 A novel l

  4. Slide 4: Objective

    Objective To examine the efficacy and safety of PHEN/TPM CR for weight loss and cardiometabolic risk reduction in overweight/obese subjects with >2 weight-related comorbidities

  5. Slide 5: CONQUER Trial Methods

    CONQUER Trial Methods Design: Phase 3 RCT of 56 weeks duration Subjects: 2487 overweight or obese subjects with >2 weight-related comorbidities (type 2 diabetes mellitus [T2DM] or prediabetes [impaired fasting glucose/impaired glucose tolerance, IFG/IGT], hypertension [HTN], hypertriglyceridemia) Li

  6. Slide 6: Proportions of Subjects With Comorbidities

    Proportions of Subjects With Comorbidities HTN (or >2 antihypertensive medications) – 53% Hypertriglyceridemia (or >2 lipid-lowering medications) – 36% Abdominal obesity – 99% T2DM or prediabetes – 68% T2DM diagnosis – 16% Prediabetes (IFG/IGT) – 67% >3 comorbidities – 51%

  7. Slide 7: Percent Weight Loss From Baseline to Week 56

    Percent Weight Loss From Baseline to Week 56 Overall Sample (ITT-LOCF) Weight loss curves are plotted with LS mean changes. *P<0.0001 vs placebo

  8. Slide 8: Proportion of Subjects Achieving Weight Loss Thresholds at Week 56

    Proportion of Subjects Achieving >5%, >10%, and >15% Weight Loss at Week 56: Overall Sample (ITT-LOCF) *P<0.0001 vs placebo

  9. Slide 9: Reduction in Waist Circumference at Week 56

    Reduction in Waist Circumference at Week 56 Overall Sample (ITT-LOCF) Shown on Y-axis is change in LS means. ITT data set consisted of subjects who took >1 dose of the study drug and had >1 post-baseline assessment. *P<0.0001 vs placebo

  10. Slide 10: Changes in Blood Pressure at Week 56

    Changes in Blood Pressure at Week 56 Overall & Hypertensive Samples (ITT-LOCF) Included in the analysis are subjects with baseline value and >1 post-baseline observation. Changes over time are depicted with changes in LS mean values. *P<0.001 vs placebo; †P<0.0001 vs placebo; ‡P<0.05 vs placebo Over

  11. Slide 11: Changes in Lipids at Week 56

    Changes in Lipids at Week 56 Overall and Hypertriglyceridemia Samples (LOCF) Included in the analysis are subjects with baseline value and >1 post-baseline observation. Changes over time are depicted with changes in LS mean values. *P<0.05 vs placebo; †P<0.0001 vs placebo Parameter Baseline mean (mm

  12. Slide 12: Change in Glycemic Parameters at Week 56

    Change in Glycemic Parameters at Week 56 Overall and T2DM Samples (LOCF) Included in the analysis are subjects with baseline value and >1 post-baseline observation. Changes over time are depicted with changes in LS mean values. *P<0.0001 vs placebo; †P<0.005 vs placebo; ‡P< 0.0005 vs placebo; §P<0.0

  13. Slide 13: Changes in Concomitant Medications From Baseline to Week 56

    Changes in Concomitant Medications From Baseline to Week 56 Changes in Concomitant Antihypertensive Medications in the Hypertensive Sample (ITT) Percentage of Subjects With: Placebo (n=516) PHEN/TPM CR 7.5/46 (n=256) PHEN/TPM CR 15/92 (n=514) Decrease 4.7% 10.5% 14.8% No change 87.2% 85.5% 80.9% Inc

  14. Slide 14: Treatment-Emergent Adverse Events (Safety Set)

    Adverse Event (Preferred Term) Placebo (n=993) (%) 7.5/46 (n=498) (%) 15/92 (n=994) (%) Dry mouth 2.4 13.5 20.8 Paresthesia 2.0 13.7 20.5 Constipation 5.9 15.1 17.4 Upper respiratory tract infection 12.9 12.2 13.4 Dysgeusia 1.1 7.4 10.4 Insomnia 4.7 5.8 10.3 Headache 9.1 7.0 10.2 Dizziness 3.1 7.2 1

  15. Slide 15: Safety Summary

    Safety Summary Most AEs were mild/moderate in severity Treatment-emergent serious AEs in the placebo, 7.5/46, and 15/92 groups were 3.8%, 2.8%, and 4.3%, respectively Overall completion rates on study drug were 57%, 69%, and 64% for placebo, 7.5/46, and 15/92, respectively Discontinuations due to ad

  16. Slide 16: Conclusions

    Conclusions Both doses of PHEN/TPM CR achieved robust weight loss in overweight/obese patients 7.8% to 9.8% vs 1.2% in placebo in overall sample (ITT-LOCF) Weight loss achieved with PHEN/TPM CR was associated with significant and clinically meaningful improvements in blood pressure, lipids, and glyc

  17. Slide 17: Questions

    Questions ——

Vivus — Technical Presentation (July 2010) on 6ix